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PERIOPERATIVE MANAGEMENTImplementation of a comprehensive blood conservation program can
reduce blood use in a community cardiac surgery programSteve Xydas, MD,a Christopher J. Magovern, MD,a James P. Slater, MD,a John M. Brown III, MD,a
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926Objective: The study objective was to determine the effects of implementing a blood conservation algorithm on
blood product use and outcomes in a community cardiac surgery program.
Methods: A blood management strategy including lower hemoglobin transfusion threshold and algorithm-
driven decisions was adopted. Intraoperatively, point-of-care testing was used to avoid inappropriate component
transfusion. A low prime perfusion circuit was adopted. Blood was withdrawn from patients before initiating
bypass when possible. Patients undergoing coronary and valve procedures were included. Outlier patients re-
ceiving more than 10 units packed red blood cells were excluded. Data were collected for 6 months as a baseline
group (group I). A 3-month period of program implementation was allotted. Data were subsequently collected
for 6 months and comprised the study patients (group II). Prospective data were collected on demographics,
blood use, and outcomes.
Results: Group I comprised 481 patients, and group II comprised 551 patients. Group II received fewer units of
packed red blood cells, fresh-frozen plasma, and cryoprecipitate than group I. There was no difference in plate-
lets transfused. Total blood product use was reduced by 40% in group II (P<.001). The overall 30-day mortality
was 1.3%. There were no differences in mortality, reoperation for bleeding, or other postoperative outcomes
between the groups.
Conclusions: Implementation of a comprehensive blood conservation algorithm can be rapidly introduced,
leading to reductions in blood and component use with no detrimental effect on early outcomes. Point-of-
care testing can direct component transfusion in coagulopathic cases, with most coagulopathic patients requiring
platelets. Further research will determine the effects of reduced transfusions on long-term outcomes. (J Thorac
Cardiovasc Surg 2012;143:926-35)Of the 30 million units of blood components transfused
each year in the United States (2006), 16 million are used
during or after a surgical procedure.1 Blood transfusions
in patients undergoing cardiac operations use 15% to
20% of the nation’s blood annual supply, and this fraction
is increasing because of increasing patient age and the
growing complexity of cardiac surgical procedures.2
Among cardiac surgical patients, it has been shown that
the benefits of transfusion are offset by risks, such as trans-
mission of infectious diseases, allergic reactions, fever, lung
injury, immunosuppression, and hemolytic reactions. These
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The Journal of Thoracic and Cardiovascular Surgis real, and far more elusive, has been the observation that
patients transfused during the perioperative period have
higher morbidity and mortality for reasons that are unex-
plained by serious transfusion hazards or concurrent medi-
cal problems.2-4 Blood transfusion also increases the cost of
the procedure both directly and by prolonging length of
stay.5,6 As a result, there have been multiple initiatives to
reduce transfusion in cardiac surgery patients.7 Indications
for transfusion currently are not standardized, as evidenced
by a wide disparity in transfusion rates.8
The ability of blood conservation initiatives to reduce
blood transfusion rates in cardiac surgery has been demon-
strated.9-11 However, the effects of point-of-care testing to
reduce blood component transfusion remain controversial,
particularly in the post-cardiopulmonary bypass setting.12,13
The effect of recently introduced and commercially
available data acquisition tools that provide procedure-
specific, surgeon-specific, and patient-specific information
on transfusion rates has not been investigated. In addition,
established transfusion guidelines have not been success-
fully in effecting change and limiting exogenous blood
transfusion in cardiac surgery,9 casting doubt on the effects
of blood conservation initiatives on transfusion practices in
community settings with diverse private practitioner groups.ery c April 2012
Abbreviations and Acronyms
FFP ¼ fresh-frozen plasma
PRBC ¼ packed red blood cell
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MThe objective of our study was to assess the impact of
a comprehensive, multidisciplinary blood conservation ini-
tiative on blood product use and clinical outcomes in our
community cardiac surgery program.
MATERIALS AND METHODS
This study was approved by the institutional review board, and written
informed consent was waived for this study.
Blood Conservation Initiative
A blood management program was implemented at Morristown Medi-
cal Center in January 2010. This initiative was led by the cardiac surgical
group (4 surgeons) and supported by the hospital administration. The strat-
egies used included lowering the hemoglobin threshold for transfusion (<7
g/dL postoperatively), as opposed to the previous physician-specific thresh-
olds ranging from 8 to 10 g/dL. Intraoperatively, a low prime perfusion cir-
cuit (Terumo Cardiovascular Systems, Ann Arbor, Mich) was adopted for
on-pump cases. The Cell Saver blood salvage system (Haemonetics, Brain-
tree, Mass) was used during surgery to recover shed blood and concentrate
residual blood in the bypass circuit after surgery. Pre-bypass phlebotomy
was also routinely performed in patients with intraoperative hemoglobin
values of 10 g/dL or more, with 500 to 600 mL of blood typically stored
and transfused after protamine administration.
Algorithm-driven decisions for red cell and component transfusion were
adopted (Figure 1). Our algorithmwas based on previously published algo-
rithms,2,14-16 but modified by our multidisciplinary task force.
Perioperatively, point-of-care testing (Ichor PlateletWorks, Helena Labora-
tories, Beaumont, Tex; i-STAT, Abbott Point of Care, Princeton, NJ) was
used to guide component therapy. Patients demonstrating signs of bleeding
intraoperatively (as deemed by the surgeon) or chest tube drainage in the
early postoperative period more than 200 mL/h had coagulation studies
performed. In these patients, fresh-frozen plasma (FFP) was administered
for an international normalized ratio greater than 1.4. Likewise, platelets
were transfused for functioning platelet counts less than 100,000, as seen
in testing for EDTA, collagen, and adenosine diphosphate assays. Cryopre-
cipitate was administered only after correction of the patient’s international
normalized ratio and platelet function with ongoing coagulopathy where
documented fibrinogen levels were less than 150 mg/dL.
Before January 2010, no specific algorithm was in place at Morristown
Medical Center guiding red cell or component transfusion. Transfusion
thresholds were solely at the clinical discretion of each individual private
practitioner. Cell Saver blood salvage system was routinely used for all
cases. Pre-bypass phlebotomy was not routinely performed. No point-of-
care testing was used.
Patient Population
All patients undergoing isolated coronary artery bypass grafting, valve
procedures, and combined valve and coronary procedures at Morristown
Medical Center were included. Data regarding patient demographics, peri-
operative blood use, and morbidity and mortality were collected during the
index hospitalization and for 30 days postoperatively. The New Jersey De-
partment of Health definitions of patient complications, as reported by the
registry data collection form, were used.17
Patients undergoing elective isolated valve surgery routinely had their
aspirin discontinued 10 days preoperatively. Patients requiring coronaryThe Journal of Thoracic and Casurgery continued their aspirin. Elective patients previously on clopidogrel
or prasugrel had these medications discontinued. Platelet inhibition studies
were performed in this patient group to confirm that inhibition was 20% or
less in patients who did not have a full 5 days of a thienopyridine ‘‘washout
period.’’
Patients undergoing surgery from July to December 2009 before strat-
egy implementation comprised the baseline comparison group (group I).
The period from January to March 2010 was allotted for adoption and im-
plementation of the blood conservation program. Patients undergoing sur-
gery from April to September 2010 comprised the study population (group
II). Outlier patients, defined as those receiving more than 10 units packed
red blood cells (PRBCs), were excluded to avoid confounding by patients
with massive blood loss.
Statistical Analysis
All statistical analyses were performed usingMINITAB (MINITABRe-
lease 15.1.1.0.; Minitab Inc, State College, Pa). Values of non-normally
distributed variables were expressed as median and range. Unadjusted dif-
ferences between groups were evaluated using chi-square or Fisher exact
tests for categoric variables (when sample sizes were small). The nonpara-
metric Mann–Whitney U test was used for continuous variables. Separate
multivariate logistic regression models for blood product and component
use were performed. All variables shown to be significant or marginally
significant (P<.10) in analyses of unadjusted differences were included
in multivariate models.RESULTS
A total of 1090 patients underwent valve or coronary sur-
gery at MorristownMedical Center during the study period;
68% of patients were male, and the median age was 70
years. Group I comprised 481 of 512 total patients, with
31 exclusions (6%) for patients receiving more than 10
units of PRBCs. Group II comprised 551 of 578 patients,
with 27 exclusions (5%). The overall 30-day mortality
was 1.3% (13/1032 patients).Baseline Patient Characteristics
Baseline patient characteristics are listed in Table 1.
Group II patients were slightly older than group I patients
(median: 69 vs 71 years, P¼ .052), although this difference
was of borderline significance. In addition, those in group II
were moderately sicker, based on New York Heart Associ-
ation class, with more class 3 and less class 2 patients
(P¼ .004). Group II also had a higher proportion of patients
with hypertension and hypercholesterolemia (89% vs 83%,
P ¼ .002; 82% vs 77%, P ¼ .029, respectively). In addi-
tion, group II had slightly lower preoperative hemoglobin
levels than group I, although this difference was of border-
line significance (median: 12.0 vs 12.2 g/dL, P ¼ .075).
There were small differences on the duration of crossclamp
and cardiopulmonary bypass times, with a longer duration
in group I than group II (median: 48 vs 44 minutes,
P ¼ .026; 70 vs 65 minutes, P ¼ .004, respectively).Blood Product and Component Use
Group II patients received significantly fewer units of al-
logeneic PRBC, FFP, and cryoprecipitate than group Irdiovascular Surgery c Volume 143, Number 4 927
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FIGURE 1. Blood conservation algorithm adopted at Morristown Medical Center in January 2010 for intraoperative (A) and postoperative (B) manage-
ment. ICU, Intensive care unit; INR, international normalized ratio; FFP, fresh-frozen plasma; PTT, prothrombin time; ACT, activated clotting time;
HgB, hemoglobin; ASA, acetylsalicylic acid.
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TABLE 1. Preoperative and intraoperative patient characteristics
(n ¼ 1032)
Group
P
value*
Group I
(N ¼ 481)
Group II
(N ¼ 551)
Preoperative characteristics
Age (y)
Median 69 71 .052
Range 22–99 31–92
Gender, male (%) 333 (69%) 370 (67%) .47
Race
White (%) 439 (91%) 503 (91%) .93
Black (%) 12 (3%) 12 (2%)
Other (%) 30 (6%) 36 (7%)
Body surface area (m2)
Median 2.0 2.0 .29
Range 1.1–2.9 1.3–3.0
NYHA class
Class 1 (%) 64 (13%) 64 (12%) .004
Class 2 (%) 212 (44%) 194 (35%)
Class 3 (%) 139 (29%) 214 (39%)
Class 4 (%) 66 (14%) 79 (14%)
Smoker (%) 250 (52%) 303 (55%) .33
Diabetes (%) 155 (32%) 174 (32%) .82
Dyslipidemia (%) 370 (77%) 454 (82%) .029
Renal failure (%) 38 (8%) 58 (11%) .15
Hypertension (%) 398 (83%) 492 (89%) .002
Cerebral vascular disease (%) 61 (13%) 92 (17%) .070
Chronic obstructive
pulmonary disease
None (%) 421 (88%) 485 (88%) .73
Mild (%) 46 (10%) 45 (8%)
Moderate (%) 10 (2%) 16 (3%)
Severe (%) 4 (1%) 5 (1%)
Myocardial infarction (%)y 151 (31%) 177 (32%) .80
Cardiogenic shock (%) 2 (<1%) 5 (1%) .46
Hemoglobin (g/dL)
Median 12.2 12.0 .075
Range 8.0–18.4 7.1–17.4
Intraoperative characteristics
Crossclamp time (min)
Median 48 44 .026
Range 8–135 13–158
CPB perfusion time (min)
Median 70 65 .004
Range 16–183 24–258
No. of graftsz
Median 3 3 .39
Range 1–6 1–5
Procedure group
CABG (%) 282 (59%) 307 (56%) .57
Valve (%) 119 (25%) 142 (26%)
ValveþCABG (%) 79 (16%) 102 (19%)
NYHA,NewYorkHeartAssociation;CPB, cardiopulmonary bypass;CABG, coronary ar-
tery bypass grafting. *Based on the chi-square test/Fisher exact test for categoric variables
and the Mann–Whitney U test for continuous variables. yMyocardial infarction refers to
events in patient history or during hospital admission but before surgery. zThe number of
coronary artery grafts refers to the number of bypass grafts performed in the patients un-
dergoing isolated coronary artery bypass grafting cases and bypass graftingþvalve cases.
TABLE 2. Blood product and blood component use (n ¼ 1032)
Units/patient
Group
P value*
Group I
(N ¼ 481)
Group II
(N ¼ 551)
Allogeneic PRBCs 2.1  2.4 1.5  2.2 <.001
Median (range) 1 (0–10) 0 (0–10)
Platelets 0.4  0.9 0.5  0.9 .75
Median (range) 0 (0–5) 0 (0–5)
FFP 1.5  3.1 0.9  2.3 .019
Median (range) 0 (0–14) 0 (0–18)
Cryoprecipitate 1.8  4.7 0.6  2.9 <.001
Median (range) 0 (0–32) 0 (0–23)
Total blood product use 5.8  9.8 3.5  6.9 <.001
Median (range) 2 (0–57) 1 (0–47)
Proportion receiving transfusion
Allogeneic PRBCs 60% 47% <.001
Platelets 26% 27% .80
FFP 24% 20% .078
Cryoprecipitate 16% 5% <.001
Any blood product use 63% 53% .003
Units of blood and component products are reported as the mean standard deviation
and the median (and range). PRBC, Packed red blood cell; FFP, fresh-frozen plasma.
*Based on the chi-square test/Fisher exact test for categoric variables and the
Mann–Whitney U test for continuous variables.
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fusion. Total blood product use, defined as the sum of allo-
geneic PRBC and component transfusions, was reduced by
40% in group II versus group I (P<.001). Likewise, the pro-
portion of patients receiving blood, cryoprecipitate, and any
blood or component products was significantly improved in
group II (Table 2). The percentage of patients receiving FFP
wasmarginally improved in group II comparedwith group I.
Of note, analysis of data from October to December 2010
(last data currently available) demonstrated a sustained de-
crease in blood, FFP, cryoprecipitate transfusions, and total
blood product use compared with group I (Figure 2).
Inclusion of all patient data with no outlier exclusion
yielded the same significant differences between groups I
and II described above with similar relative reductions in
transfusions of blood, FFP, cryoprecipitate, and total blood
product use in group II versus group I (data not shown).
Patient Outcomes
There were no differences in the rates of in-hospital mor-
tality, 30-day mortality, length of stay, reoperation for
bleeding, perioperative myocardial infarction, prolonged
ventilator support, atrial fibrillation, or other postoperative
complications between the groups (Table 3). Group II
patients had a slightly lower predischarge hemoglobin level
than group I patients (median: 9.5 vs 9.9 g/dL, P<.001).
Multivariate Analysis
Given the clinical differences in baseline patient charac-
teristics between the patient cohorts (Table 1), multivariate
analyses predicting the use of blood transfusions andrdiovascular Surgery c Volume 143, Number 4 929
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FIGURE 2. Blood transfusion and blood component use over time. A 3-month period of blood conservation algorithm implantation was allotted from
January to March 2010. FFP, Fresh-frozen plasma; PRBC, packed red blood cell.
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significant differences in the patient groups. In this multi-
variate model, group II was associated with significantly
less allogeneic blood transfusions compared with group I
(P<.001; Table 4). In addition, older age, preoperative re-
nal failure, longer cardiopulmonary bypass time, and de-
creased preoperative hemoglobin were all associated with
higher transfusion rates (P<.05).
Likewise, group II had substantially lower transfusion
rates of FFP and cryoprecipitate in multivariate analyses
(Tables 5 and 6, respectively). Group II was associated
with lower total blood product transfusion rates than
group I (Table 7).
DISCUSSION
Blood transfusions during the perioperative period have
been associated with significantly worse morbidity and930 The Journal of Thoracic and Cardiovascular Surgmortality.2-4 Transfusion therapy also increases the cost of
cardiac procedures.5,6 In addition, substantial variability
in the transfusion rates of PRBC and blood components
exists in patients undergoing cardiac surgery.8 Despite con-
sensus statements endorsing a 7 g/dL hemoglobin ‘‘trigger’’
for red cell transfusion and a recent randomized trial sup-
porting the adoption of lower transfusion thresholds in car-
diac surgery patients,18 application is compromised by
confusion concerning indications and risks of transfusion,
as well as fear of litigation.2 In addition, established trans-
fusion guidelines have not been successful in effecting
change and limiting exogenous blood transfusion in cardiac
surgery,9 casting doubt on the effects of blood conservation
initiatives on transfusion practices in community settings
with diverse private practitioner groups. In the setting of
present fiscal realities, it is therefore no surprise that there
have been growing initiatives to reduce transfusions inery c April 2012
TABLE 3. Postoperative patient outcomes (n ¼ 1032)
Variable
Group
Difference (95% CI)* P valueyGroup I (N ¼ 481) Group II (N ¼ 551)
Hospital mortality (%) 4 (1%) 5 (1%) <1% (1% to 1%) 1.00
Mortality 30 d (%) 4 (1%) 9 (2%) <1% (2% to 1%) .25
Postoperative LOS (d) 6 (0–48) 6 (2–70) 0 (0.0001 to 0.0001) .97
Postoperative bleeding with
Reoperation (%) 20 (4%) 22 (4%) <1% (2% to 3%) .89
Myocardial infarction (%) 1 (<1%) 0 (0%) .47
Deep sternal wound infection (%) 1 (<1%) 3 (1%) .63
Sepsis (%) 5 (1%) 4 (1%) <1% (<1% to 1%) .74
Transient ischemic attack (%) 3 (1%) 4 (1%) <1% (1% to 1%) 1.00
Prolonged ventilator support
(% with>24 h) 44 (9%) 57 (10%) 1% (4% to 2%) .52
Pulmonary embolism (%) 1 (<1%) 3 (1%) .63
Renal failure (%) 15 (3%) 17 (3%) <1% (2% to 2%) .98
Dialysis (%) 6 (2%) 4 (1%) 1% (<1% to 2%) .53
Cardiac arrest (%) 8 (2%) 5 (1%) 1% (1% to 2%) .28
Multiorgan system failure (%) 1 (<1%) 0 (0%) .47
Atrial fibrillation (%) 112 (23%) 125 (23%) 1% (4% to 6%) .82
Predischarge hemoglobin (g/dL) 9.9 (8–15) 9.5 (7.5–13.3) 0.4 (0.2–0.5) <.001
CI, Confidence interval; LOS, length of stay. *Difference in rate and 95% CI are not shown for comparisons with small event numbers (1 event). yBased on the chi-square test/
Fisher exact test for categoric variables and the Mann–Whitney U test for continuous variables.
Xydas et al Perioperative Managementcardiac surgery,7 and consensus statements support the
adoption of multimodality blood management programs
and transfusion algorithms.2 In this context, our methodol-
ogy sheds light on the feasibility of such a blood conserva-
tion program.
We sought to determine whether a comprehensive blood
program could be successfully adopted in a large
community-based program. Our approach included a trans-
fusion algorithm adopting a lower routine hemoglobin
transfusion threshold, prebypass blood withdrawal andTABLE 4. Multivariate logistic regression model for allogeneic red
blood cell transfusion (n ¼ 1032)
Factor Mean or%* OR 95% CI P value
Group (II vs I) 53.4% 0.35 (0.26–0.48) <.001
Age (per 10 y) 69.0 1.74 (1.52–1.99) <.001
NYHA class 2 39.3% 0.95 (0.60–1.50) .81
NYHA class 3 34.2% 1.49 (0.93–2.40) .10
NYHA class 4 14.1% 1.30 (0.74–2.28) .36
Dyslipidemia (yes vs no) 79.8% 0.98 (0.67–1.44) .91
Preoperative renal failure
(yes vs no)
9.3% 4.49 (2.39–8.41) <.001
Hypertension (yes vs no) 86.2% 0.77 (0.48–1.22) .27
CPB perfusion time
(per 10 min)
72.8 1.16 (1.03–1.32) .017
Crossclamp time
(per 10 min)
49.9 0.98 (0.83–1.15) .78
Preoperative
hemoglobin (per g/dL)
12.0 0.74 (0.68–0.80) <.001
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; OR, odds ratio;
CI, confidence interval. *An overall average is reported for continuous variables, and
an overall percentage (of the total sample size) is reported for categoric variables.
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pathic patients, cell salvage, and use of a miniature
low-prime circuit. The program is easy to implement but
necessitates a rigorous multidisciplinary effort from all per-
sonnel: the surgeons, perfusionists, anesthesiologists, inten-
sive care unit nursing staff, intensivists, transfusion
medicine staff, and cardiologists.
To facilitate the adoption of this strategy, we embarked
on programmatic intervention that included (1) educational
sessions for providers involved in the care of our patients
where the baseline data were shared and the rationale for re-
ducing blood was explained; (2) formation of a blood man-
agement task force that included representatives from
surgery, anesthesia, perfusion, and nursing and was empow-
ered to create the program and the transfusion algorithm and
monitor adoption; (3) small group education for intensive
care unit and floor nurses; and (4) ongoing analysis of
data using IMPACT Online (Haemonetics), a comprehen-
sive blood management tool that provides procedure-
specific, surgeon-specific, and patient-specific information
regarding blood transfusion rates. As a result of our multi-
faceted blood conservation plan, a sustained 40% overall
reduction in blood product use was observed. No differ-
ences in early outcomes were seen.
Although we observed an overall 29% reduction in allo-
geneic PRBCs transfused, there was only a small difference
in predischarge hemoglobin levels between groups I and II.
We therefore speculate that most of the decrease we wit-
nessed in transfusion rates was a result of our inoperative
blood conservation strategy (as opposed to the lower hemo-
globin transfusion threshold). The use of point-of-carerdiovascular Surgery c Volume 143, Number 4 931
TABLE 5. Multivariate logistic regression model for fresh-frozen
plasma transfusion (n ¼ 1032)
Factor Mean or%* OR 95% CI P value
Group (II vs I) 53.4% 0.70 (0.50–0.98) .040
Age (per 10 y) 69.0 1.48 (1.26–1.74) <.001
NYHA class 2 39.3% 1.20 (0.67–2.15) .55
NYHA class 3 34.2% 1.76 (0.99–3.15) .056
NYHA class 4 14.1% 1.62 (0.83–3.18) .16
Dyslipidemia (yes vs no) 79.8% 1.09 (0.71–1.66) .70
Preoperative renal failure
(yes vs no)
9.3% 2.33 (1.42–3.82) .001
Hypertension (yes vs no) 86.2% 0.53 (0.32–0.88) .015
CPB perfusion time
(per 10 min)
72.8 1.26 (1.11–1.43) <.001
Crossclamp time
(per 10 min)
49.9 1.03 (0.88–1.21) .71
Preoperative
hemoglobin (per g/dL)
12.0 0.94 (0.87–1.03) .18
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; OR, odds ratio;
CI, confidence interval. *An overall average is reported for continuous variables, and
an overall percentage (out of the total sample size) is reported for categoric variables.
TABLE 7. Multivariate logistic regression model for any blood
product transfusion (n ¼ 1032)
Factor Mean or%* OR 95% CI P value
Group (II vs I) 53.4% 0.45 (0.33–0.61) <.001
Age (per 10 y) 69.0 1.61 (1.41–1.84) <.001
NYHA class 2 39.3% 1.10 (0.70–1.72) .68
NYHA class 3 34.2% 1.61 (1.01–2.58) .046
NYHA class 4 14.1% 1.40 (0.81–2.43) .23
Dyslipidemia (yes vs no) 79.8% 0.95 (0.65–1.39) .79
Preoperative renal
failure (yes vs no)
9.3% 4.34 (2.26–8.31) <.001
Hypertension (yes vs no) 86.2% 0.70 (0.45–1.12) .14
CPB perfusion time
(per 10 min)
72.8 1.19 (1.04–1.35) .008
Crossclamp time
(per 10 min)
49.9 0.98 (0.84–1.15) .83
Preoperative
hemoglobin (per g/dL)
12.0 0.78 (0.72–0.84) <.001
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; OR, odds ratio;
CI, confidence interval. *An overall average is reported for continuous variables, and
an overall percentage (of the total sample size) is reported for categoric variables.
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circuit, and pre-bypass blood withdrawal is therefore likely
to have made most of the impact in lower blood product use.
According to the reported adverse effect of transfusion
during cardiac surgery,2-4 the lower use of blood products
should have a positive impact on clinical outcomes, which
was not observed in the short-term follow-up in this study.
The low baseline early mortality (1%) would require
a larger sample size to show a significant difference.
What we demonstrate is that a blood conservation program
can be implemented that decreases transfusion without ad-
ditional risk to the patients. Although previous studies haveTABLE 6. Multivariate logistic regression model for cryoprecipitate
transfusion (n ¼ 1032)
Factor Mean or%* OR 95% CI P value
Group (II vs I) 53.4% 0.18 (0.11–0.32) <.001
Age (per 10 y) 69.0 1.26 (1.01–1.56) .038
NYHA class 2 39.3% 0.85 (0.38–1.91) .69
NYHA class 3 34.2% 1.27 (0.57–2.84) .56
NYHA class 4 14.1% 1.63 (0.66–4.04) .29
Dyslipidemia (yes vs no) 79.8% 1.12 (0.62–2.01) .71
Preoperative renal failure
(yes vs no)
9.3% 2.53 (1.32–4.85) .005
Hypertension (yes vs no) 86.2% 0.58 (0.30–1.14) .12
CPB perfusion time
(per 10 min)
72.8 1.24 (1.06–1.45) .008
Crossclamp time
(per 10 min)
49.9 1.06 (0.86–1.31) .57
Preoperative
hemoglobin (per g/dL)
12.0 0.94 (0.83–1.07) .36
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; OR, odds ratio;
CI, confidence interval. *An overall average is reported for continuous variables, and
an overall percentage (of the total sample size) is reported for categoric variables.
932 The Journal of Thoracic and Cardiovascular Surgtried to address these questions, many were retrospective
analyses11 or had a limited sample size.10
The effects of point-of-care testing to reduce blood com-
ponent transfusion remain controversial, particularly in the
post-cardiopulmonary bypass setting.12,13,19 Our algorithm
reduced the use of PRBC, FFP, and cryoprecipitate
transfusion but did not affect platelet use. The likely
rationale for this lack of reduction in platelet transfusion
is that point-of-care testing frequently identified platelet
function abnormalities as the source of coagulopathy. The
results of this testing thus allowed us to tailor blood compo-
nent therapy to patients’ needs, which typically meant that
platelets were given at similar rates but FFP and cryopreci-
pitate use declined. However, we cannot exclude the possi-
bility that our criteria for platelet transfusion (functioning
platelets < 100,000 in bleeding patients) were overly
lenient.
Our blood conservation program was able to reduce our
transfusion rates from above the national Society of Tho-
racic Surgeons’ average to rates at or below the national av-
erage. For example, for 2009, the postoperative transfusion
rate for patients undergoing isolated coronary artery bypass
reported by the Society of Thoracic Surgeons was 49.5%
versus an average of 43.4% in ‘‘like’’ regional cardiac pro-
grams and a national average of 45.5%. Post-intervention,
our transfusion rates for patients undergoing isolated coro-
nary artery bypass grafting was 40.0% (over the 9-month
period of January to September 2010) versus an average
of 40.1 in ‘‘like’’ regional cardiac programs and a national
average of 42.4%. Comparable improvements were seen
in patients undergoing isolated valve and combined valve/
coronary surgery. Our findings of reduced blood and com-
ponent use with a concerted blood management initiativeery c April 2012
Xydas et al Perioperative Managementcan likely apply to most cardiac surgery programs at or
above national transfusion rates.Study Limitations
The limitations of this study include those inherent to
nonrandomized trials using historical control groups. There
were minor baseline differences between our patient
groups. These changes include small differences in patient
age, New York Heart Association class, and rates of hyper-
tension and hypercholesterolemia. Group II was therefore
a slightly older and sicker cohort of patients who may rep-
resent slight changes in referral patterns in our clinical prac-
tice over time. Given these small differences, group II may
be expected to have a slightly higher inherent risk of trans-
fusion than group I. In addition, the sustained decreases in
blood and component transfusion suggest that these de-
creases are attributable to our blood conservation initiative.
This study was not designed to include patients who are tra-
ditionally at higher risk for bleeding, such as those having
ventricular assist device implantation or thoracic aortic sur-
gery. Outcome analysis was limited to early mortality and
morbidity, and more extensive study is needed that evalu-
ates the effects of a blood conservation strategy on long-
term patient outcomes.
Although an integrated blood conservation initiative led
to broad adoption at Morristown Medical Center, blood
transfusion thresholds did, in some instances, vary in the
postoperative period on the basis of clinical judgment.
Last, the data reported do not include an analysis of cost.
Real cost-savings should be evaluated in a more extensive
study that includes not only the savings associated with de-
creased transfusion but also the cost of implementation of
a blood conservation protocol (eg, use of cell salvage, staff
education, and point-of-care testing).P
MCONCLUSIONS
Systematic implementation of a comprehensive blood
conservation algorithm can be rapidly introduced in a com-
munity-based cardiac surgery program, leading to signifi-
cant reductions in blood and blood component use and
with no measurable effect on early patient mortality and
morbidity. Point-of-care testing can successfully direct
blood component transfusion in patients with coagulopathy.
Further research will determine the effects of reduced trans-
fusions on long-term outcomes of patients undergoing car-
diac surgery.
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Dr James Maxwell (Missoula, Mont). Allogeneic blood trans-
fusion has been under intense review for the last decade, and
a 2006 review inCirculation referred to post-cardiac surgery trans-
fusions as a silent epidemic. Significant evidence of the harmful
effects of transfusion have accumulated to the point where the cur-
rent search is for meaningful evidence to support transfusion ab-
sent life-threatening hemorrhage. Still, the frequency ofrdiovascular Surgery c Volume 143, Number 4 933
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Mtransfusion after cardiac surgery in the United States varies widely
from 0% to 75%. It is in this context that the authors implemented
a comprehensive blood conservation program in a community hos-
pital. The study is actually a retrospective comparison of historical
controls versus transfusion rates after coronary artery bypass graft-
ing, valve, and combined cases. The statistical analysis suggested
a reduction in transfusion of FFP, red blood cells, and cryoprecipi-
tate. Despite stopping aspirin for 10 days preoperatively, a reduc-
tion in platelet transfusion was not noted. For reasons unclear,
excluded from analysis from both groups were outliers requiring
more than 10 units of blood, although the statistical impact of
this was nil. A 41% reduction in blood transfusion was achieved
over the study period and persisted for the 3 months after the study
interval. The post-study transfusion rate was approximately 50%
for the combined group. There were no differences in major mor-
bidity between the groups. Despite improvements in transfusion
rates, no reductions in prespecified morbidity were noted. I also
note the overall excellent results of your group across the board
for surgical outcomes, which may explain why there was no im-
provement in surgical outcomes despite improvements in blood
use.
I have thousands of questions actually because this is a great
topic, but I will limit my questions to 3.
Did you follow preoperative and discharge hemoglobin levels?
If so, what were the discharge hemoglobin levels?
You mentioned intraoperative cerebral oximetry in your article,
although not in the presentation this morning. Do you have an in-
traoperative transfusion trigger based on intraoperative measure-
ments of cerebral oximetry?
Given that there was no difference in platelet transfusions, do
you still exclude aspirin for 10 days preoperatively in patients
with coronary disease given the known positive impact of aspirin
in the coronary artery bypass grafting group?
Dr Xydas. In terms of the comment about the outliers, it was
our statistical consultants who thought that cases with more than
10 red blood cells should be excluded. We ran the analysis with
or without these exclusions, and the results were the same, al-
though overall average numbers of transfusions were obviously
higher where we did not exclude those numbers, but the relative
reductions were the same with both analyses.
In terms of hemoglobin, we did track that in the 2 patient
groups. The baseline hemoglobin was no different between the
groups. The nadir hemoglobin, which was interesting to us, was
no different. It was 8.8 for both patient groups. The last hemoglo-
bin before the patient going home was slightly different. It was
a statistical difference. It decreased to 9.7 from 10.0 between group
II and group I. The conclusions we drew were that most of the re-
ductions in blood we sawmay have been more a result of the blood
conservation portions as opposed to the changes in thresholds of
hemoglobin with time, although likely it was both factors that
were involved, though the overall differences in the post-hemoglo-
bin even before discharge were small but different.
In terms of cerebral oximetry, our threshold for hemoglobin in
routine cases for transfusion was 6.0 on pump. We use cerebral
oximetry and carotid studies preoperatively to guide individual pa-
tient decisions. If there were cases of cerebrovascular disease that
was significant on carotid studies or a decrease in the baseline ce-
rebral oximetry on pump into the red zone, we did initially just934 The Journal of Thoracic and Cardiovascular Surgchange pH management to try to fix this. If they were still in the
red so to speak in terms of the changewith time as opposed to base-
line cerebral oximetry, we increased the hemoglobin threshold
from to 7 from 6. This was a decision we made intraoperatively.
In terms of the postoperative stroke incidence, it was no differ-
ent at 30 days between the patient groups, so it seemed at least in
the early postoperative mortality and morbidity to be safe in terms
of lowering these hemoglobin thresholds.
In terms of not seeing improvements in outcomes over time, this
was approximately 500 patients (group I vs II), and we only looked
through 30 days, so likely we would have needed higher patient
numbers to be statistically powered to see any small improvements
in terms of our initiatives with time. Certainly future studies with
longer term outcomes are going to address these questions.
DrRichard Shemin (Los Angeles, Calif). As you know, the So-
ciety of Thoracic Surgeons’ workforce on evidence-based surgery
has an excellent guidelines manuscript that is being reviewed and
another version coming out on the various blood conservation
strategies that I think we could all use.
How many of your patients came to the operating room so ane-
mic that they required a blood transfusion despite a low prime vol-
ume? Often, when we institute these blood conservation strategies,
we can see an immediate impact, but sustaining it over time is of-
ten a challenge because people lapse back into old habits? Have
you continued your task force? Do you continue to monitor to
maintain your good results?
Dr Xydas. The algorithms recently published were the impetus
and laid the groundwork for much of our program, and that was
overall helpful to have on a national front in terms of an impetus
for this kind of program.
In terms of the on-pump transfusion rates, they were approxi-
mately 35% and slightly lower in group II as opposed to group I in-
traoperatively. Postoperatively there was still a fair amount of
blood given in the postoperative period. I mentioned the differ-
ences in the hemoglobins. There were no differences in the nadir
but differences that were small in terms of the postdischarge hemo-
globin. We did tend to see relatively late transfusions, which
thwarted a lot of our effort, and so itwas really amatter of a 3-month
period of trying to bring home this message to everyone involved
(pulmonologists, cardiologists, intensive care unit, nurses) and of
quarterly analysis that are key. We did not see a decline in benefits
that we saw in the 3-month follow-up period, but certainly there is
going to still be that inertia to go back to the old method, so it is
going to be important to continue bringing that message home
with time and continuing with the task force, which are our plans.
I mentioned it was a 40% overall decrease in blood transfusion
rates. We were most effective in reducing cryoprecipitate and FFP
administration as opposed to blood, likely for those reasons in
terms of anyone being able to give blood even where we had the
strategy employed. In the future, wemaymake it mandatory to dis-
cuss with the surgeon or to okay an order for blood before going
forward. We just wanted to do this gently to make this palatable
for everybody, but certainly the easy one was the FFP and the cry-
oprecipitate, namely, for cryotherapy our rates of transfusion de-
creased by 67% with the point-of-care testing versus
coagulopathic patients receiving transfusions of FFP and platelets.
Platelets primarily were necessary on postoperative point-of-care
testing.ery c April 2012
Xydas et al Perioperative ManagementI know there was a question about the aspirin. We stop that rou-
tinely for isolated valve cases without coronary disease. It did not
seem tomake a difference, and that was really just the effects of the
pump on platelet function with time more so than the effects of the
aspirin perioperatively.
Dr Danny Chu (Houston, Tex). This is a great program. I con-
gratulate you for doing this. Have you seen any barriers in adopting
this program? If so, what are your suggestions for overcoming
those barriers in terms of having surgeons not adopting these
guidelines and what not?
Dr Xydas. The first buy-in has to be with the surgeons. In our
program there are only 4, and it really led by us wanting to do
this that helped bring the message home. To us, that was the easiestThe Journal of Thoracic and Capart of it, to see the data and guidelines in terms of their change,
and having this buy-in and making it something we would cham-
pion with time. We had multiple grand rounds with the cardiolo-
gists. That was where it really took more time. There are
always, ‘‘Well, this guy is going to have ischemic optic neuritis,
I’ve seen it 20 years ago, wemust give blood,’’ those sort of discus-
sions, which are not evidenced-based and just a matter of being dil-
igent and absolutely ongoing in terms of the efforts of education
with time. That is where it takes an effort longitudinally because
there is a tendency to have a decrease that is immediate that makes
you feel good but certainly a tendency to go back up with inertia of
the old habits, so that is where I think a lot of the bulk of the effort
has to be long term.rdiovascular Surgery c Volume 143, Number 4 935
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